BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Phase 3
Completed
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 270
- Registration Number
- NCT00111007
Research Study for Patients With Metastatic Renal Cell Carcinoma
Phase 2
Terminated
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-05-09
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1
- Registration Number
- NCT00110344
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Phase 2
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: Doxorubicin/Placebo
- First Posted Date
- 2005-04-22
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 96
- Registration Number
- NCT00108953
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Phase 3
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-03-15
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 602
- Registration Number
- NCT00105443
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
Phase 3
Completed
- Conditions
- HypertensionPostmenopause
- Interventions
- Drug: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)Drug: Placebo
- First Posted Date
- 2005-01-24
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 750
- Registration Number
- NCT00102141
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small Cell LungCancer
- Interventions
- First Posted Date
- 2005-01-11
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 52
- Registration Number
- NCT00101413
BAY43-9006 - Phase II in Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Breast NeoplasmsBreast Cancer
- Interventions
- First Posted Date
- 2005-01-11
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 54
- Registration Number
- NCT00101400
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
Phase 3
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2004-12-16
- Last Posted Date
- 2008-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2244
- Registration Number
- NCT00099502
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- Leukemia
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Bayer
- Registration Number
- NCT00086775
- Locations
- 🇺🇸
Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: Placebo
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 501
- Registration Number
- NCT00079612
© Copyright 2025. All Rights Reserved by MedPath